Oncolytic viruses, which exclusively target and break down cancer cells, have the potential to revolutionize standard cancer treatment. Though researchers are continuing to pursue the optimization of these viruses and their manufacture through a variety of viral engineering strategies, their continued progress hinges on meeting a number of goals linked to safety, efficacy, and commercial scale-up. These include high virus yields, highly reproducible key quality attributes, genetic stability, and formulation and product stability goals.
Download the paper using the widget on the right >>>
Download the paper using the widget on the right >>>